Reirradiation and Erbitux in the HNSCC

Inclusion Criteria:

* Patient with unresectable locoregional recurrence of squamous cell carcinoma in a previously irradiated area (at least 75% of the volume of recidivism must be in an area who have received at least 50 Gy)
* The entire tumor volume can be included in a radiation field without the total dose to the spinal cord more than 50 Gy (dose + dose earlier predicted)
* Patient with recurrent or second location in the oral cavity, oropharynx, larynx, hypopharynx, cervical lymph nodes or tissues, without distant metastases,
* Minimum 12 months after the end of radiotherapy previous
* WHO performance status: 0-1,
* Evaluable disease by RECIST V.1.1.,
* Age between 18 and 75 years
* The patient may have received prior chemotherapy for relapse for more than five weeks,
* The patient may have received cetuximab for the treatment of disease but not for the first relapse,
* Hematologic function: ANC ≥ 1500/mm3, Platelets ≥ 100000/mm3,
* Normal renal function: serum creatinine ≤ 120 µmol/l and/or creatinine clearance \> 60 ml/min
* Normal liver function: bilirubin \<1.5 x ULN, alkaline phosphatase and transaminases \<2.5 x ULN,
* Normal cardiac function, assessed clinically. History of cardiovascular disease stabilized for over 12 months
* Cons-Lack of medical indications in the proposed treatment,
* The dosimetry of previous treatment should be available and the estimated dosimetry must be performed to check the constraints,
* All patients of childbearing age should receive effective contraception,
* Membership of a social security system (or be a beneficiary of such a plan) under the terms of the Act of August 9, 2004,
* Signed informed consent

Exclusion Criteria:

* Tumors of the nasal cavity and paranasal,
* Tumors of other histological type,
* Stage IV with distant metastases or multiple tumors,
* Time after previous radiotherapy \<12 months,
* Less than 75% of the volume of relapse who have previously received at least 50 Gy,
* Any medical condition or general-cons would indicate the completion of treatment. Systemic disease or uncontrolled infection,
* History of cancer other than head and neck cancer, cutaneous basal cell, carcinoma in situ of the cervix
* Any other concurrent anticancer therapy,
* Patient receiving another molecule experimental
* Pregnant, lactating or without contraception;
* Persons deprived of liberty under guardianship
* Inability to undergo medical test for geographical, social or psychological
* Nasopharyngeal Neoplasms
* Patients with active ischemic heart disease or previous myocardial infarction within the last 12 months
* Late toxicity dermal or subcutaneous related to previous irradiation of grade\> 2 in the scale CTCAE V.4.